Discontinued — last reported Q1 '21

Other

Stock-Based Comp

Insmed Stock-Based Comp remained flat by 0.0% to -$14.85M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 372.5%, from -$3.14M to -$14.85M. Over 2 years (FY 2023 to FY 2025), Stock-Based Comp shows a downward trend with a 393.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementIncome Statement
SectionOther
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ2 2019
Last reportedQ1 2021

How to read this metric

Higher values indicate a larger tax disadvantage associated with equity-based incentive programs.

Detailed definition

This metric represents the portion of share-based compensation expenses that are not tax-deductible under current tax la...

Peer comparison

Commonly disclosed by technology and growth companies with significant equity compensation programs.

Metric ID: other_income_tax_reconciliation_nondeductible_expense_sh_6983a4

Historical Data

3 years
 FY'23FY'24FY'25
Value$2.44M-$12.57M-$59.41M
YoY Change—-614.7%-372.5%
Range-$59.41M – $2.44M
CAGR+393.1%
Avg YoY Growth-493.6%
Median YoY Growth-493.6%
Current Streak2+ years decline

Frequently Asked Questions

What is Insmed's stock-based comp?
Insmed (INSM) reported stock-based comp of -$14.85M in Q4 2025.
How has Insmed's stock-based comp changed year-over-year?
Insmed's stock-based comp decreased by 372.5% year-over-year, from -$3.14M to -$14.85M.
What is the long-term trend for Insmed's stock-based comp?
Over 2 years (2023 to 2025), Insmed's stock-based comp has grown at a 393.1% compound annual growth rate (CAGR), from $2.44M to -$59.41M.
What does stock-based comp mean?
The amount of stock-based compensation that cannot be deducted for tax purposes.